TDM for Optimized Outcome in Patients With mRCC.

Plain-language summary

This study evaluates therapeutic drug monitoring (TDM) — measuring the blood level of the active metabolite of the cancer treatment — in patients with metastatic renal cell carcinoma. People in Denmark receiving medical treatment for metastatic renal cell carcinoma can take part. This study without an assigned phase is ongoing and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Niels Fristrup

Intervention

Measurement of concentration of active metabolite in cancer treatment.

Start date

11/1/2020

Estimated completion

8/31/2029

Countries

Denmark

Related genes

Locations

• Aarhus, Denmark

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients in Denmark with medically treated metastatic renal cell carcinoma.

Exclusion Criteria:

* No written informed consent.